Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Вирус, ассоциированный с аденовирусом (AAV), в качестве вектора для генной терапии
2017-07-01
SCID: 54.1/vk4z9vzj
Discuss with AI
AAVAdeno-associated virusgene deliverygene therapy vectorsrecombinant AAV
Figures from the paper
Abstract (AI)
There has been a resurgence in gene therapy efforts that is partly fueled by the identification and understanding of new gene delivery vectors. Adeno-associated virus (AAV) is a non-enveloped virus that can be engineered to deliver DNA to target cells, and has attracted a significant amount of attention in the field, especially in clinical-stage experimental therapeutic strategies. The ability to generate recombinant AAV particles lacking any viral genes and containing DNA sequences of interest for various therapeutic applications has thus far proven to be one of the safest strategies for gene therapies. This review will provide an overview of some important factors to consider in the use of AAV as a vector for gene therapy.
Key Findings
1
AAV has attracted significant attention for clinical-stage experimental therapeutic strategies.
2
Adeno-associated virus (AAV) can be engineered to deliver DNA to target cells for therapeutic applications.
3
Recombinant AAV particles lacking viral genes and carrying therapeutic DNA are considered one of the safest gene therapy strategies.
4
The paper reviews important factors to consider when using AAV as a vector for gene therapy.
Research Object
Adeno-associated virus (AAV) as a gene delivery vector
Research Subject
Factors affecting the use of AAV for gene therapy, including engineering recombinant AAV particles (lacking viral genes) to deliver therapeutic DNA and considerations for clinical-stage applications and safety
Publication Details
Publication Date
2017-07-01
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest